Literature DB >> 6132975

Hypophysectomy does not prevent increased cerebral dopamine turnover following sulpiride administration.

L M Reynolds, R G Dyer, P Jenner, C D Marsden.   

Abstract

Hypophysectomy is claimed to prevent increased forebrain dopamine turnover produced by administration of sulpiride. We have measured the increase in dopamine metabolite concentrations caused by sulpiride following surgical removal of the pituitary. In saline-treated control animals and in hypophysectomized rats 1 week or 1 month following surgery, administration of sulpiride caused marked elevations of striatal, nucleus accumbens and tuberculum olfactorium, homovanillic acid (HVA) and 3,4-dihydroxyphenylacetic acid (DOPAC) concentrations which were maximal 4-8 h following drug administration. The maximal increases in nucleus accumbens and tuberculum olfactorium were generally comparable in control and hypophysectomized animals, except for a greater increase in HVA levels in the nucleus accumbens 1 month following hypophysectomy. However, maximal increases in HVA and DOPAC in striatum were more pronounced in hypophysectomized rats 1 week or 1 month following surgery compared with control animals. At 30 min following sulpiride administration only inconsistent changes in dopamine turnover were observed in both control and hypophysectomized rats. Hypophysectomy does not prevent sulpiride from increasing forebrain dopamine turnover suggesting this is due to a direct interaction with cerebral dopamine receptors.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6132975     DOI: 10.1111/j.2042-7158.1983.tb04299.x

Source DB:  PubMed          Journal:  J Pharm Pharmacol        ISSN: 0022-3573            Impact factor:   3.765


  2 in total

Review 1.  Psychotropic properties of ovarian estrogens (review).

Authors:  E B Arushanyan; G K Borovkova
Journal:  Neurosci Behav Physiol       Date:  1989 Jan-Feb

2.  Autoradiographic study of 14C-sulpiride in monkey.

Authors:  A Benakis; J P Brown; P Benard
Journal:  Eur J Drug Metab Pharmacokinet       Date:  1984 Oct-Dec       Impact factor: 2.441

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.